Globus Medical에 대한 매도 수량은 투자자에게 Globus Medical의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Globus Medical (NYSE:GMED) 주식, 공매도 수량 보고

Globus Medical

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Earnings

Equities

News

Pre-Market Outlook

Markets

GMED

QCOM

SMCI

미국 주식 선물이 수요일 아침 (현지 시간 기준) 상승세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들이 다음과 같다: 1. CVS 헬스(NYSE:CVS)가 분기 이익을 주당 1.53달러, 매출을 927억 5천만 달러로 예상하는 가운데, 월스트리트는 개장 전 발표를 기다리고 있다. CVS 헬스의 주가는 애프터 마켓에서 0.7% 상승해 55.70달러로 거래되었다.

수요일 주목해야 할 주식: CVS 헬스, 글로버스 메디컬, 존슨 컨트롤스, 퀄컴 및 슈퍼 마이크로

Globus Medical, Inc. Class A Common Stock

Globus Medical Inc

Barclays analyst Brandon Oglenski maintains Expeditors Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) with a Underweight and raises the price target from $105 to $110.

Price Target

Analyst Ratings

EXPD

Barclays Maintains Underweight on Expeditors Intl, Raises Price Target to $110

Trading Ideas

SONN

Sonnet BioTherapeutics Shares Halted On Circuit breaker To The Downside, Stock Now Up 106.9%

WIIM

Origin Bancorp shares are trading higher. DA Davidson maintained a Buy rating on the stock.

FUFU

BiFuFu shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a price target of $7.

Pagaya Technologies shares are trading higher after the company announced it raised $1 billion across two new personal loan and auto ABS deals.

Trump Media & Technology Group Shares Halted To The Downside; Stock Now Up 24.31%

STOK

Stoke Therapeutics shares are trading higher on possible continued strength following Q3 reported financial results yesterday. Also, Needham and HC Wainwright & Co. reiterated Buy ratings on the stock.

Editor's Note: The headline has been corrected to indicate recent downgrades.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc analyst Steve Barger downgraded the rating for Myers Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Overweight to Sector Weight. Myers shares closed at $11.39 on Tuesday. <a href="https://www.benzinga.com/quote/mye/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Vivien Azer downgraded the rating for Brown-Forman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Buy to Hold and lowered the price target from $50 to $48. Brown-Forman shares closed at $43.74 on Tuesday. <a href="https://www.benzinga.com/quote/bf.b/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Samik Chatterjee downgraded Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) from Neutral to Underweight and slashed the price target from $50 to $23. Super Micro Computer shares closed at $27.70 on Tuesday. <a href="https://www.benzinga.com/quote/smci/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Kevin Fischbeck downgraded Ardent Health Partners, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) from Buy to Neutral and lowered the price target from $22 to $19. Ardent Health Partners shares closed at $18.05 on Tuesday. <a href="https://www.benzinga.com/quote/ardt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Oren Livnat downgraded the rating for Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Buy to Neutral. Verrica Pharmaceuticals shares closed at $0.7975 on Tuesday. <a href="https://www.benzinga.com/quote/vrca/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CHWY stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06084847/image-52-1024x514.png" alt="" class="wp-image-632811" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06084847/image-52-1024x514.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06084847/image-52-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06084847/image-52-768x385.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06084847/image-52.png 1232w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Downgrades

ARDT

VRCA

This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday (CORRECTED)

Barclays analyst Julian Mitchell maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Equal-Weight and raises the price target from $103 to $116.

Barclays Maintains Equal-Weight on Emerson Electric, Raises Price Target to $116

American Express Global Business Travel, which is operated by Global Business Travel Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) ("Amex GBT" or the "Company"), a leading software and services company for travel, expense and meetings &amp; events, has confirmed today that the U.K. Competition and Markets Authority (the "CMA") has published its interim report regarding Amex GBT's proposed acquisition of CWT, a global business travel and meeting solutions provider. Amex GBT fundamentally disagrees with the CMA's interim assessment that the transaction may result in a substantial lessening of competition in the UK and it will continue to work collaboratively with the CMA to demonstrate that the transaction should be approved by the CMA.
The Company believes that the CMA's interim report does not reflect the evidence presented on the highly competitive and dynamic nature of the business travel sector. Instead, the CMA has erroneously focused on a narrow segment that makes up a small fraction of business travel spend. The CMA has ignored multiple sources of evidence that show clearly that Amex GBT consistently competes for all customers, including the largest global customers, with numerous other travel management companies that operate globally.
Amex GBT will respond to the interim report to correct several errors and misconceptions about how the business travel sector operates and to demonstrate that the CWT acquisition will not harm competition in the UK or elsewhere. The acquisition of CWT will create synergies and provide greater capacity for investment and innovation. It will also create more choice for customers and more efficient distribution for suppliers while maintaining a highly competitive environment for business travel services.
Amex GBT will in parallel continue to work collaboratively with other regulators, including the Antitrust Division of the U.S. Department of Justice, in their review of the transaction. The Company continues to expect the transaction to close in the first quarter of 2025.

Legal

GBTG

American Express Global Business Travel Notes U.K. Competition And Markets Authority's Interim Report Regarding CWT Acquisition; Says 'Amex GBT Fundamentally Disagrees With The CMA's Interim Assessment That The Transaction May Result In A Substantial Lessening Of Competition In The UK And It Will Continue To Work Collaboratively With The CMA To Demonstrate That The Transaction Should Be Approved'

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged to a new record high, touching $75,358 during early Wednesday trading in Europe and surpassing its previous <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37660169/bitcoin-breaks-73-000-mark-reaching-4-new-highs-in-less-than-a-week">peak of $73,737 from Mar. 14</a>, as <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">Donald Trump beat Kamala Harris</a> to win the 2024 election.
Although it later pulled back slightly to $73,879, the cryptocurrency maintained a strong 6.7% gain over the last day, according to CoinGecko <a href="https://www.coingecko.com/en/coins/ethereum">data</a>.
In contrast, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) showed more modest activity, trading at $2,618 and remaining 46% below its all-time high of $4,878 from November 2021. 
The ongoing momentum has largely favored Bitcoin as the asset draws heightened interest amid a positive regulatory outlook following the U.S. election.
U.S. Election Sparks Renewed Optimism For Crypto Investors
The market's rally follows the election results, with President-elect Donald Trump's <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41710293/bitcoin-could-hit-90-000-if-trump-wins-hold-50-000-floor-under-harris-bernstein">pro-crypto stance</a> and the support of new crypto-friendly policymakers driving enthusiasm.
In a note sent to Benzinga, Samir Kerbage, CIO at Hashdex, emphasized that the election results were a positive development for the crypto industry. 
"We've been conveying to clients in recent months that the U.S. election, regardless of the specific outcome, will be a net positive for crypto investors," he noted. "Yesterday's results were ideal given the pro-crypto stance of President-elect Trump and many newly elected policymakers."
Bitcoin's swift rise reflects the anticipation that Trump's administration will appoint key figures supportive of the industry, which could lead to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41650250/harris-vs-trump-crypto-industry-anticipates-favorable-regulatory-environment-for-bi">favorable policy shifts</a>.
"In the last 24 hours, Trump's support for Bitcoin and the crypto industry is already impacting prices," Kerbage said. "This history, along with Bitcoin's typical post-halving outperformance and ongoing institutional adoption, sets the asset class up for a strong 2025."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41746095/what-the-election-outcome-means-for-bitcoins-near-term-price-action">What The Election Outcome Means For Bitcoin&#8217;s Near-Term Price Action</a>
Bitcoin Drives Market Cap Surge As Euphoria Spreads
Bitcoin's momentum also fueled the overall cryptocurrency market, pushing its total capitalization up by 7% to $2.45 trillion within a day, briefly peaking at $2.48 trillion. 
Alex Kuptsikevich, FxPro&#8216;s chief market analyst, told Benzinga that Bitcoin&#8217;s is a key driver of the rally. 
He noted that the rally remains within a rising channel established since September, with indicators suggesting further upside potential.
Meme coin Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) also saw a significant boost, rallying 55% from early November lows. 
Kuptsikevich attributes part of Dogecoin&#8217;s jump to speculation about Elon Musk's <a href="https://www.benzinga.com/news/24/11/41766808/mark-cuban-congratulates-trump-musk-before-the-election-is-called-says-they-won-fair-and-square">possible role</a> in the new administration, as Musk has long been a proponent of the coin.
Navigating U.S. Crypto Regulation: Calls For A Balanced Framework
Despite the positive sentiment, experts stress the need for clear regulatory direction in the U.S. 
Anthony Yeung, Global Head of Strategic Development at CoinCover, cautioned that while Trump has promised to make the U.S. the &#8220;crypto capital&#8221; of the world, the specifics of his regulatory plans remain uncertain.
 "The details of his plans are yet to be seen, and it will take time to understand his full stance," Yeung explained. "It's in the interest of the industry that the U.S. moves sooner rather than later when it comes to crafting a regulatory framework."
Yeung warned that delays in U.S. regulation could allow the EU's MiCA legislation to set global standards.
 "If the U.S. continues to govern by enforcement without clear guidelines, there's a risk it will lose influence over shaping the regulatory landscape in coming years," he added, advocating for a framework that balances innovation with consumer protection.
Future Of Crypto Looks Strong Amid Political Shifts
Looking forward, experts anticipate a strong year for digital assets, supported by Bitcoin's post-election history and favorable conditions. 
According to Kerbage, "In the six months following the last three presidential elections, Bitcoin has seen triple-digit returns." 
He expects this trend to continue, driven by Trump's potential crypto-friendly appointments and a Congress that is more supportive of digital assets than ever before. 
However, he advises caution amid short-term uncertainties, acknowledging the need for a strategic regulatory framework to sustain growth.
Investors and enthusiasts can look forward to deeper discussions on these trends at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where prominent voices in the sector will explore the potential impact of policy changes, the future of digital asset adoption, and strategies for navigating market volatility.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41725148/first-uk-pension-scheme-allocates-3-to-bitcoin">First UK Pension Scheme Allocates 3% To Bitcoin</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

Bitcoin Hits New All-Time High As Donald Trump Wins Second Term: What Now?

Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 13.37%. Currently, Wheaton Precious Metals has a market capitalization of $28.32 billion. 
Buying $1000 In WPM: If an investor had bought $1000 of WPM stock 10 years ago, it would be worth $3,650.89 today based on a price of $62.43 for WPM at the time of writing.
<h3>Wheaton Precious Metals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730903441_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Wheaton Precious Metals 10 Years Ago Would Be Worth This Much Today

Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) has outperformed the market over the past 20 years by 8.67% on an annualized basis producing an average annual return of 16.89%. Currently, Equinix has a market capitalization of $87.71 billion. 
Buying $1000 In EQIX: If an investor had bought $1000 of EQIX stock 20 years ago, it would be worth $22,505.32 today based on a price of $908.99 for EQIX at the time of writing.
<h3>Equinix's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730903436_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

$1000 Invested In This Stock 20 Years Ago Would Be Worth $23,000 Today

BEAM

Beam Therapeutics shares are trading higher after Leerrink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $27 to $39.

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 35.72 million shares sold short, which is 27.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730903424_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 12.35%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NVAX

How Is The Market Feeling About Novavax?

AutoZone's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) short percent of float has fallen 8.74% since its last report. The company recently reported that it has 425 thousand shares sold short, which is 2.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AutoZone Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730903419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AutoZone has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AutoZone's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AutoZone's peer group average for short interest as a percentage of float is 12.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(AZO) - Analyzing AutoZone's Short Interest

PJT Partners's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>) short percent of float has fallen 7.51% since its last report. The company recently reported that it has 1.14 million shares sold short, which is 6.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PJT Partners Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730903413_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PJT Partners has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PJT Partners's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PJT Partners's peer group average for short interest as a percentage of float is 3.16%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into PJT Partners's Recent Short Interest

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares are soaring Wednesday morning after Donald Trump was elected the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">47th president of the United States</a>.
What Happened: Shares of Trump Media, the parent company of social media platform&nbsp;Truth Social,&nbsp;are surging Wednesday after Trump defeated Vice President Kamala Harris in the 2024 presidential race, driving several stocks expected to benefit under a Trump presidency higher.
Trump owns a majority stake in Trump Media &amp; Technology Group, which has nearly tripled off the September lows as of the time of writing. Broader markets are also rising in early trading led by the Russell 2000 Index as investors expect U.S.-focused growth companies to benefit from potential lower taxes, per Reuters.
&#8220;The market believes a Trump presidency will unleash animal spirits and give a boost to growth in the short-term through some relief on corporate taxes and deregulation,&#8221; Frédérique Carrier, head of investment strategy for RBC Wealth Management, reportedly said. 
Some of the outsized gains on Wednesday may be due to optimism surrounding a potential Republican sweep. Republicans have won control of the U.S. Senate and the White House. The U.S.&nbsp;House&nbsp;of Representatives is still yet to be determined.
&#8220;If you look at historical playbook, a Republican sweep has been strong backdrop for the S&amp;P 500 whereas a Republican presidency with a split Congress has given a more muted return,&#8221; Carrier reportedly said.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/11/41769412/dow-nasdaq-futures-race-higher-as-trump-wins-white-house-djt-tesla-shares-surge-veteran-investor-pr">Dow, Nasdaq Futures Race Higher As Trump Wins White House: DJT, Tesla Shares Surge — Veteran Investor Predicts US Economy Could &#8216;Take Off&#8217;</a>
Several Trump-linked stocks were moving Wednesday morning including Phunware Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) and Rumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>). Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares were up more than 12% at last check as Tesla CEO Elon Musk has been a strong supporter of Trump throughout his campaign, and Trump has said he would put Musk in charge of a <a href="https://www.benzinga.com/government/24/09/40739165/trump-plans-to-appoint-elon-musk-to-government-efficiency-commission-if-elected-tesla-ceo-says-hell">government efficiency commission</a>. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also jumped to record highs Tuesday night as Trump has positioned himself a pro-crypto. He said earlier this year that he wanted all Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39289772/donald-trump-wants-all-the-remaining-bitcoin-to-be-made-in-the-usa">to be made in the U.S.</a> Crypto-linked stocks like MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) were moving significantly higher. Several Bitcoin mining stocks were also moving higher at last check. 
DJT Price Action: Trump Media shares were up 30.3% at $44.22 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Politics

Movers

COIN

MSTR

PHUN

TSLA

Trump Media & Technology Group Stock Is Surging Wednesday: What's Going On?

Barclays analyst Duffy Fischer maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Underweight and raises the price target from $84 to $85.

Barclays Maintains Underweight on DuPont de Nemours, Raises Price Target to $85

AVDX

AvidXchange Holdings shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 revenue guidance.

Globus Medical ( ($GMED) ) has released its Q3 earnings. Here is a breakdown of the information Globus Medical presented to its investors. Globus M...

Globus Medical Reports Robust Q3 2024 Financial Growth

BTIG analyst Ryan Zimmerman maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $87.00. The company'...

BTIG Sticks to Its Buy Rating for Globus Medical (GMED)

Wells Fargo analyst Vik Chopra raised the firm's price target on Globus Medical (GMED) to $88 from $78 and keeps an Overweight rating on the shares...

Globus Medical price target raised to $88 from $78 at Wells Fargo

Wells Fargo analyst Vik Chopra has assigned their bullish stance on GMED stock, giving a Buy rating yesterday. Vik Chopra has given his Buy rating ...

Globus Medical's Strong Q3 Performance and Optimistic Outlook Justify Buy Rating

Truist Financial analyst Richard Newitter maintained a Hold rating on Globus Medical (GMED – Research Report) today and set a price target of $85.0...

Truist Financial Sticks to Its Hold Rating for Globus Medical (GMED)

Piper Sandler Reaffirms Their Buy Rating on Globus Medical (GMED)

Piper Sandler analyst Matt O'Brien raised the firm's price target on Globus Medical (GMED) to $100 from $80 and keeps an Overweight rating on the s...

Globus Medical price target raised to $100 from $80 at Piper Sandler

Stifel analyst Mathew Blackman raised the firm's price target on Globus Medical (GMED) to $92 from $80 and keeps a Buy rating on the shares. Q3 "se...

Globus Medical price target raised to $92 from $80 at Stifel

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

RBC Capital raised the firm's price target on Globus Medical (GMED) to $92 from $80 and keeps an Outperform rating on the shares. The company issue...

Globus Medical price target raised to $92 from $80 at RBC Capital

ATHM

AUDC

CELH

ENOV

EXAS

HNDAF

IONS

IRBT

VERX

Press Releases

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Domino's and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED

GMED Investors Have Opportunity to Join Globus Medical, Inc. Securities Fraud Investigation with the Schall Law Firm

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the Firm

General

Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

Health Care

Globus Medical to Participate in Orthopedic Trauma Association Annual Meeting

Globus Medical Reports Third Quarter 2024 Results

CUBI

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Piper Sandler

B of A Securities

BTIG

RBC Capital

Barclays

Globus Medical shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

Comments

Globus Medical

매도 수량

Globus Medical (NYSE:GMED) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌